Dean Remy Email & Phone Number

Boston, Ma, Us

San Francisco, Us

Our Team is launching an AI-driven and IoT-enabled 3D/4D Virtualization Platform empowering Intelligent crisis and emergency response and global facility smart-management.

Co-launching a newco to develop both rapid POC and confirmatory tests for high-risk and ectopic pregnancies.

Responsibilities: Create commercial strategy around the co-development and technological partnerships, alliances, and KOL's; develop forecasts for the CRO business; build and manage the BD Team in the U.S & /EU; implement a CRM and necessary sales tools; build the initial C-Suite, Scientific and Investor Databases of @10K contacts; Lead Generation, Contract Negotiations, Implement nurturing campaigns; build partner relationships to contract signing; create Press Releases; create and manage website updates; created a monthly newsletter; created scientific animation video; designed company collateral materials; designed company trade show booth for first commercial presence; attend and oversee company conference participation; deliver weekly updates and reports to the CEO; organized meetings with all Top 20 large pharma and hundreds of small-to-mid-sized pharma; provided lead on setting up investor meetings and follow-on conversations; and enabled the repositioning of the company from a platform CRO to a hub-and-spoke model with Therapeutic Co-Development as well as ownership of our own cancer therapeutic assets.Now possessing cell-based assets ready to take on Pancreatic, Ovarian, Colorectal, Prostate cancers and Glioblastomas; Spanios is transforming fast-therapeutic efficacy assessments into transformative cures. By harnessing the powerful capabilities of stably generated and biobanked Patient Derived Tumoroids ((PDTs) aka Tumor Organoids), we enable the accelerated development & validation of drugs for rare and non-rare cancers. Our platform uses patient-derived 3D tumor models that enable scientists to fast-track the search for novel cures and bring hope to millions of patients. This TME enabled platform with-or-without PBMC's and physiologic blood flow allow for the most human-like small molecule, antibody, peptide, ADC, VHH, synthetic lethality, CAR-T/NK/Mac or other IO therapeutic efficacy testing possible flipping the drug validation paradigm on its head.

South San Francisco, Ca, Us

Responsible for creating internal infrastructure and processes improvements to support the new North American BD efforts for the Marseille-site (formerly DBA Halio Dx). Identifying and securing contractual relationships & legal agreements with top global and well-funded pharmaceutical companies developing cancer therapeutic for the provision of custom Cancer ATLAS Data and Subscription Pan-Cancer ATLAS Data licensing; Decipher GRID RWD Data licensure; and, for services supporting their Tumor-microenvironment (TME) Multiomic (Immunomic. Proteomic, Transcriptomic, Genomic) studies. ● Identify and develop cancer data development or out-licensing opportunities with pharma/biopharma key decision-makers ● Expand North American prospect list and details for MARCOM and BD outreach efforts● Establish U.S. Pricing Sheet for Marseille-based Services and Tools● Redesign of SFDC Implementation to ensure proper opportunity tracking and forecasting● Deliver weekly reporting to Marseille Site Head Veracyte offers customized biomarker testing and analytical services to our biopharmaceutical partners, helping them advance their therapeutic discovery, development and commercialization programs. We do this by leveraging our novel insights into the molecular underpinnings of disease and our extensive experience in drug development.Veracyte is a unification of best-in-class companies including Decipher Biosciences, Inc., and HalioDx, Veracyte's proprietary AI/ML tools, data visualization, tumor immune contexture, multiparametric tissue analysis, biomarker discovery, Transcriptomics, TME insights and our immuno-oncology offerings focus on the implications of the tumor micro environment using tools such as Immunoscore®, Immunosign®, our Brightplex® innovative technology, our Immunogram multimodal analysis platform and our Cancer Immune Atlas dedicated database.

Wilmington, Massachusetts, Us

Responsible for building and managing a small BD team and training & supporting the Discovery BD representatives and BD Management globally on large molecule opportunities. Identifying and securing contractual relationships & legal agreements with top global and well-funded pharmaceutical companies developing therapeutic antibodies, scFv, “knob-and-Hole bispecifics, BiTE’s, Fab’s, IgG’s and nanobodies (VHH’s) for the provision of custom therapeutic protein discovery and optimization service solutions. • Identify and develop out-licensing opportunities within vaccine, biopharmaceutical, CAR-T/NK/MAC and Cell & Gene Therapy companies of libraries & internal lead asset candidates.• Ensure appropriate strategic solution is proposed to customer including customized Scopes of Work (SOW), pricing, service proposals and Master Service Agreements. Worked closely with our bioinformatic, structural biology, immunology, bioanalytic, and other necessary scientific teams.• Introduced process reducing SOW turn-around from 4-5 weeks to 5-7 days and initiated program for secure, digital scope of work data capture and integration into SFDC to facilitate more complete automation of SOW preparation.• Create seamless cross-functional opportunities for the integration of the antibody discovery business unit into the larger organization • Assure development of new messaging around “large molecule discovery” within presentations, web pages, social media content, slide decks and more.• Personally helped increase antibody library licensure opportunities 4x over prior 2.5 years combined. • Expedite license contracts and master service agreement through the contract negotiation process for rapid execution. • Paved the way with several opportunities for strategic partnerships and/or acquisitions related to large molecule therapeutic validation.

Took leave to care for a family member nearly passing due to COVID-19

South San Francisco, California, Us

Responsible for identifying and securing contractual relationships and legal agreements with top global and well-funded pharmaceutical companies developing therapeutic antibodies, nanobodies (VHH’s) for the provision of custom therapeutic protein discovery and optimization service solutions. • Identify and develop COVID-19 therapeutic and diagnostic partners for licensing of the company’s internally developed antibodies and nanobodies. • Ensure appropriate strategic solution is proposed to customer, monitoring actions and results against plans.• Assure key risks and opportunities are identified, captured, and presented in an unbiased way to senior management for decision making.• Drive contribution and consensus from colleagues for scientific, legal, logistics, finance, and commercial functions, leading term sheet and contract negotiations• Expedite term sheets and master service agreements through the contract negotiation process for execution with velocity.• Closed company's largest co-development deal with a Top 3 Pharma for 13 Programs over 3 years with M&R's and downstream commercials.

Hoddesdon, Herts, Gb

Responsible for strategic planning & partnerships securing new contractual relationships and legal agreements with most Top 20 global key pharma institutions, AgBio and Aquaculture organizations and Research Institutes for provision of custom service solutions, instrumentation and products.• Drove above market growth rates for sciences manufacturing and services company whose genomic division provides ultra-high throughput (uHT) sample extraction and purification, qPCR instruments, tissue probes, research kits, reagents, custom GMP/RUO DNA and RNA design and synthesis, NGS library prep tools and custom cells and enzymes, PCR systems and products, genomics solutions, custom kit builds, DNA sequencing, custom genotyping assay build and services, DELs, analytical services and testing products.• Analyzed potential opportunities and develop sales plans for each target account. • Adapted successful strategies and tactics to meet market demands and financial targets.

Created and implemented the clinical trial validation and confirmatory protocols for all company 510k submittals involving NASA, Emory University, Sigma Aldrich, Becton Dickinson, and QUEST Diagnostics. ● Provided scientific direction and new market justification for the company product offering.● Assisted with initial fundraising for $2M to enable pilot scale development and initial in-house testing, validation, and quality assurance (QA). ● Obtained FDA equivalent status for first product and initiated trials for 3 additional portfolio products.

Created and implemented the clinical trail validation and confirmatory protocols for all company 510k submittals involving NASA, Emory University, Sigma Aldrich, Becton Dickinson, and QUEST Diagnostics. • Provided scientific direction and new market justification for the company product offering.• Assisted with initial fundraising for $2M to enable pilot scale development and initial in-house testing, validation, and quality assurance (QA). • Obtained FDA equivalent status for first product and initiated trials for 3 additional portfolio products.

Boston, Massachusetts, Us

• Built and executed a strategy for outreach and navigation of new large pharmaceutical accounts.• Successfully communicated and positioned services to key stakeholders from current clients, to prospects, to board members, and investors. • Develop strategic alliances and partnerships to bolster the company capabilities and offerings.• Worked cross-functionally with product and operational leadership to ensure proper sales and product solution alignment.• Implemented company-wide Customer Relationship Management (CRM) and Marketing program use and trainings. • Developed the contract research organization (CRO) services contracts, pricing strategies, and created the value-prospectus.SmartLabs (formerly Mass Innovation Labs) now occupies 3 commercial properties around the life science hub of Boston/Cambridge. Clients successfully launched included: CRISPR, Editas, C4 Therapeutics, Cellaria, Radius Health, Gritstone Oncology, CUE Pharma, TCR2 Therapeutics, WaveGuide, Oncorus, Helixnano, EdiGene, Kernal Biologics, LEAP Therapeutics and others.

Fully oversaw biologic development site operations, management, sales and eventual restructuring for impending sale of entire entity to AbClonal. Six-month contract term.

Westborough, Ma, Us

Responsible for sales performance; interpreted sales data analytics and market insights in order to translate into actionable strategies for the global sales team.• Directed, inspired, coached, and motivated Regional Directors sales management and representatives to accomplish sales goals, managed large strategic contract negotiations.• Provided data support for FDA, EU and assisted D-MAH with Japanese Medical Device submissions including STED for several pharmaceutical and medical device clients during their PMDA.• Increased Life Science business by 203% in first 10 months and added 31 active referral accounts to company resources. • 2011, 29% new client sales growth | 2012, 23% new client sales growth| 2013, 24% new client sales growth.

Us

Most of the adaptations that could improve upon sales processes are counter to the infrastructure that most companies have implemented over the last 5-25 years. "The impediments to increasing sales in this new era are often institutionalized by the manufacturers themselves. Building a framework around a strategic and modular sales model, and offering it for a price point that is sensitive to the needs of small to midsized companies, will be the mode embraced by manufacturers and service providers now and in the future. Outsourced Sales Teams level the playing field, drastically improve everyone’s ROI, and enable the average sized company to compete for sales revenues anywhere and anytime." SCiSOURCE INC and LLC were founded to demonstrate and make available a dynamic new option for Scientific Sales. It takes advantage of the industry’s "Best-of-the-Best" and designs programs to motivate, retain, and respect the value they bring to the clients table. It also meets the needs of clients for focused attention, to maintain price integrity and high margins, to represent their product or service with a "Best-in-Class" method, and to bring their product to market quickly creating a barrier to entry and before the competition has an opportunity to take advantage of a limited presence. Our objective is to quickly identify, penetrate, demonstrate, and close sales faster and more efficiently than ever before possible. Technological specialties included Neuroscience, Cancer/Oncology, Microbiology, Cellular & Molecular Biology, Bioprocessing & Manufacturing, UHT Transfection tech, Ion Channel, PMDK/Toxicology, Automation, Protein Analysis & Characterization, Crystallography, In Vivo Imaging, Infrared (and NIR tech), Bioinformatics, Clinical and Molecular Diagnostics, Immunology and Therapeutic Hypothermia.

Basel, Ch

Germany based amaxa manufactured a scientifically advanced system for the reproducible transfection system for work in primary mammalian and cell lines. Joined amaxa to build Industrial Sales Strategy with launch of new higher throughput technologies. Established tiered pricing programs for large Pharma customer base and generated and implemented nationwide Scientific Seminar Program. Customized protocol development and contract service program development proved key to maximizing the amaxa sales potential. After achieving designed growth goals, amaxa was acquired by Lonza in early 2008.

Lincoln, Ne, Us

Managed the Sales & Business Development objectives for the Northeast U.S. and Eastern Canada for the LI-COR Bioscience' DNA Sequencing and Infrared Imaging systems including InVivo Imaging systems. Identified new application opportunities for IR and coordinated field evaluations.

Radnor, Pa, Us

Washington, Dc, Us

Performed laboratory testing supervision supporting all shifts. Performed sample collection (phlebotomy), processing and result confirmations. Performed all CLIA and CAP required Quality Control record-keeping and the necessary Clinical Laboratory Services including Chemistry, Special Chemistry, Immunology, Hematology, Coagulation, Urinalysis, Microscopy, Blood Banking and Microbiology. Also performed new assay and equipment validation studies, CAP testing, assisted new employee training, and monitored quality control.

Managed Eastern U.S. Sales and client integration of an artificial intelligence-based automated Microscope & Software System (Micro21 HSA) at key targeted accounts. Additionally performed AI Software training on leukemic cell differentiation to enable systems to more efficiently identify the cellular variations optically resultant from variable staining methods and techniques.

Emeryville, California, Us

Forchheim, De

Brought on for launch of ACS:180 automated immunoassay platform providing in-house and field top-level support leading to development of System & Assay Troubleshooting programs including our proprietary A.I. Bright System. Was responsible for sales and technical support plus issue escalation and resolution for Key Accounts including Corning Clinical Laboratory (Quest) and Roche Diagnostics.Advanced to Product Management roles responsible for key components of the ADVIA Centaur System and played supportive role on projects Diamond Review Committee responsible for system specifications and progress towards each. Specialized in analysis of the User Interface Design of the software system and several of the individual hardware components for the Centaur. System was integrated into the Bayer Diagnostics portfolio of laboratory automation systems and remains a global device "Gold Standard." System is currently part of Siemens Healthcare Immunological System portfolio and is renowned for its throughput and catalog of over 100 on-the-fly assay capability.

Boston, Ma, Us

Oversaw laboratory operations during night shifts. Performed required sample collection, processing and result confirmations. Performed all CLIA and CAP required Quality Control record-keeping and the Clinical Laboratory Services including Chemistry, Immunology, Hematology, Urinalysis and Microbiology. Performed also Electrocardiograms (ECG's) and, when necessary, STAT Blood Gas collection.